When a US man is told his PSA test looks worrying, the next step is usually the same one urologists have used for decades.
A needle biopsy of the prostate, guided only by ultrasound. In much of Europe, Canada, Australia and the UK, that conversation now starts with an MRI scan first, a shift that can spare many men a biopsy altogether and helps doctors zero in on the tumors that actually matter.
American practice is lagging. A large analysis of US insurance claims covering 872,829 prostate biopsies found that just 35.5 percent of biopsies were preceded by an MRI in 2022, up from a vanishingly small 0.5 percent in 2007.
The study, led by researchers at Stanford University School of Medicine and published in Prostate Cancer and Prostatic Diseases in September 2024, is the clearest picture yet of a gap that plays out across roughly 333,830 new prostate cancer cases the American Cancer Society expects in 2026.
Also read: Throw these cans away immediately, neurologist warns
What a pre-biopsy MRI actually does
Multiparametric MRI, often shortened to mpMRI, uses detailed magnetic-resonance images to look for suspicious areas inside the prostate before any needle goes in.
If the scan is clean, many men can safely postpone or avoid a biopsy. If it flags a lesion, the urologist can aim the needles at the suspicious spot instead of taking a scattered sample of tissue.
The evidence behind the approach comes from the landmark PRECISION trial published in the New England Journal of Medicine in 2018.
The multicenter randomized study, which enrolled 500 men across 23 sites in 11 countries, found that using MRI before biopsy and targeting only the suspicious areas identified clinically significant prostate cancer in 38 percent of men, compared with 26 percent for standard ultrasound-guided biopsy.
Also read: These natural remedies may help relieve pain, nausea, and restlessness
The MRI-first arm also detected fewer of the low-grade tumors that many men would be better off never knowing about.
Where US and international guidelines stand
Guidelines have moved. The National Comprehensive Cancer Network lists mpMRI as a Category 1 recommendation for men being evaluated for a possible biopsy, its highest evidence tier.
The American Urological Association's 2026 amendment to its early-detection guideline states that clinicians "may use magnetic resonance imaging (MRI) prior to initial biopsy to increase the detection of Grade Group (GG)2+ prostate cancer." For men facing a repeat biopsy who have never had an MRI, the AUA calls the scan a strong recommendation.
The 35.5 percent uptake shows how slowly practice has caught up with the science, and where you live matters.
Also read: Scientists identify 5 sleep types, each linked to distinct brain wiring and health risks
The Stanford analysis found that Minnesota reached 47.3 percent utilization in 2019 to 2022, while Mississippi sat at 14.4 percent and Arkansas at 15.2 percent. Urban patients received a pre-biopsy MRI in 36.1 percent of cases in 2022, rural patients in 28.3 percent.
What it means for patients
Prostate cancer touches about 1 in 8 American men in their lifetimes and is expected to cause around 36,320 deaths in 2026, according to the American Cancer Society. Most tumors grow slowly.
The dilemma for doctors and patients is separating the aggressive cancers that need treatment from the indolent ones that do not, without putting every man through an invasive biopsy that can cause infection, bleeding and anxiety.
For men whose PSA test comes back elevated, or who are weighing a repeat biopsy after a negative first one, guidelines now support asking a urologist about an MRI before any needles are scheduled.
Also read: 12 foods with surprisingly high protein that most people overlook
Availability varies by hospital and region, and the quality of the scan and its interpretation depend on the center's experience with prostate imaging. Any decisions about testing and treatment belong in a conversation with a doctor who knows the patient's PSA history and overall health.
Also read: New pill could replace injections for high cholesterol